Effect of Lorenzo’s Oil on Hepatic Gene Expression and the Serum Fatty Acid Level in abcd1-Deficient Mice

  • Masashi MoritaEmail author
  • Ayako Honda
  • Akira Kobayashi
  • Yuichi Watanabe
  • Shiro Watanabe
  • Kosuke Kawaguchi
  • Shigeo Takashima
  • Nobuyuki Shimozawa
  • Tsuneo Imanaka
Research Report
Part of the JIMD Reports book series (JIMD, volume 38)


Lorenzo’s oil is known to decrease the saturated very long chain fatty acid (VLCFA) level in the plasma and skin fibroblasts of X-linked adrenoleukodystrophy (ALD) patients. However, the involvement of Lorenzo’s oil in in vivo fatty acid metabolism has not been well elucidated. To investigate the effect of Lorenzo’s oil on fatty acid metabolism, we analyzed the hepatic gene expression together with the serum fatty acid level in Lorenzo’s oil-treated wild-type and abcd1-deficient mice. The change in the serum fatty acid level in Lorenzo’s oil-treated abcd1-defcient mice was quite similar to that in the plasma fatty acid level in ALD patients supplemented with Lorenzo’s oil. In addition, we found that the hepatic gene expression of two peroxisomal enzymes, Dbp and Scp2, and three microsomal enzymes, Elovl1, 2, and 3, were significantly stimulated by Lorenzo’s oil. Our findings indicate that Lorenzo’s oil activates hepatic peroxisomal fatty acid β-oxidation at the transcriptional level. In contrast, the transcriptional stimulation of Elovl1, 2, and 3 by Lorenzo’s oil does not cause changes in the serum fatty acid level. It seems likely that the inhibition of these elongation activities by Lorenzo’s oil results in a decrease in saturated VLCFA. Thus, these results not only contribute to a clarification of the mechanism by which the saturated VLCFA level is reduced in the serum of ALD patients by Lorenzo’s oil-treatment, but also suggest the development of a new therapeutic approach to peroxisomal β-oxidation enzyme deficiency, especially mild phenotype of DBP deficiency.


ABCD1 DBP ELOVL Lorenzo’s oil Very long chain fatty acid X-linked adrenoleukodystrophy 



We thank Akiko Ohba, Kayoko Toyoshi, and Noritake Taniguchi for technical assistance. This research was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (16K09961, 15H04875, 15K15389). Pacific Edit reviewed the manuscript prior to submission.

Supplementary material

464154_1_En_32_MOESM1_ESM.docx (55 kb)
Supplementary Fig. 1 Changes in body weight of LO-treated mice. Wild-type (WT) and abcd1-deficient (KO) 4-week-old mice (n = 4) were supplemented with or without LO for 5 weeks and weighed every 3 or 4 days. Intake of dietary LO was an average of 26 g/kg body weight/day. The values for the LO-treated mice were not significantly different from the non-treated mice in either WT or KO mice (PPTX 42 kb)
464154_1_En_32_MOESM2_ESM.pptx (52 kb)
Supplementary Fig. 2 Effect of Lorenzo’s oil on C26:0 level in liver. Wild-type (WT) (n = 4) and abcd1-deficient (KO) mice (n = 4) were fed with or without LO for 5 weeks as in Table 1. The liver was prepared from each mouse and subjected to gas chromatography analysis. Values are the mean ± S.E. (n = 4 animals. *, p < 0.02) (PPTX 41 kb)


  1. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC et al (1993) A two-year trial of oleic and erucic acids (“Lorenzo’s oil”) as treatment for adrenomyeloneuropathy. N Engl J Med 329:745–752CrossRefPubMedGoogle Scholar
  2. Berger J, Gartner J (2006) X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta 1763:1721–1732CrossRefPubMedGoogle Scholar
  3. Bremer J, Norum KR (1982) Metabolism of very long-chain monounsaturated fatty acids (22:1) and the adaptation to their presence in the diet. J Lipid Res 23:243–256PubMedGoogle Scholar
  4. Brolinson A, Fourcade S, Jakobsson A, Pujol A, Jacobsson A (2008) Steroid hormones control circadian Elovl3 expression in mouse liver. Endocrinology 149:3158–3166CrossRefPubMedGoogle Scholar
  5. De Craemer D, Van den Branden C, Fontaine M, Vamecq J (1998) Effects of Lorenzo’s oil on peroxisomes in healthy mice. Prostaglandins Other Lipid Mediat 55:237–244CrossRefPubMedGoogle Scholar
  6. Deon M, Garcia MP, Sitta A et al (2008) Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect. Metac Brain Dis 23:43–49CrossRefGoogle Scholar
  7. Ferdinandusse S, Denis S, Mooijer PA et al (2001) Identification of the peroxisomal β-oxidation enzymes involved in the biosynthesis of docosahexaenoic acid. J Lipid Res 42:1987–1995PubMedGoogle Scholar
  8. Ferdinandusse S, Denis S, Mooyer PA et al (2006a) Clinical and biochemical spectrum of D-bifunctional protein deficiency. Ann Neurol 59:92–104CrossRefPubMedGoogle Scholar
  9. Ferdinandusse S, Kostopoulos P, Denis S et al (2006b) Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukencephalopathy with dystonia and motor neuropathy. Am J Hum Genet 78:1046–1052CrossRefPubMedPubMedCentralGoogle Scholar
  10. Fourcade S, Ruiz M, Guilera C et al (2010) Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet 19:2005–2014CrossRefPubMedGoogle Scholar
  11. Jump DB (2009) Mammalian fatty acid elongases. Methods Mol Biol 579:375–389CrossRefPubMedPubMedCentralGoogle Scholar
  12. Kobayashi T, Shinnoh N, Kondo A, Yamada T (1997) Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem Biophys Res Commun 232:631–636CrossRefPubMedGoogle Scholar
  13. Kozawa S, Honda A, Kajiwara N et al (2011) Induction of peroxisomal lipid metabolism in mice fed a high-fat diet. Mol Med Rep 4:1157–1162PubMedGoogle Scholar
  14. Morita M, Kawamichi M, Shimura Y, Kawaguchi K, Watanabe S, Imanaka T (2015) Brain microsomal fatty acid elongation is increased in abcd1-deficient mouse during active myelination phase. Metab Brain Dis 30:1359–1367CrossRefPubMedGoogle Scholar
  15. Morita M, Shinbo S, Asahi A, Imanaka T (2012) Very long chain fatty acid β-oxidation in astrocytes: contribution of the ABCD1-dependent and -independent pathways. Biol Pharm Bull 35:1972–1979CrossRefPubMedGoogle Scholar
  16. Moser AB, Jones DS, Raymond GV, Moser HW (1999) Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochem Res 24:187–197CrossRefPubMedGoogle Scholar
  17. Moser HW (1997) Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 120:1485–1508CrossRefPubMedGoogle Scholar
  18. Moser HW, Raymond GV, Lu SE et al (2005) Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch Neurol 62:1073–1080CrossRefPubMedGoogle Scholar
  19. Murphy CC, Murphy EJ, Golovko MY (2008) Erucic acid is differentially taken up and metabolized in rat liver and heart. Lipids 43:391–400CrossRefPubMedGoogle Scholar
  20. Neat CE, Thomassen MS, Osmundsen H (1981) Effects of high-fat diets on hepatic fatty acid oxidation in the rat. Isolation of rat liver peroxisomes by vertical-rotor centrifugation by using a self-generated, iso-osmotic, Percoll gradient. Biochem J 196:149–159CrossRefPubMedPubMedCentralGoogle Scholar
  21. Ofman R, Dijkstra IM, van Roermund CW (2010) The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO Mol Med 2:90–97CrossRefPubMedPubMedCentralGoogle Scholar
  22. Restuccia D, Di Lazzaro V, Valeriani M et al (1999) Neurophysiologic follow-up of long-term dietary treatment in adult-onset adrenoleukodystrophy. Neurology 52:810–816CrossRefPubMedGoogle Scholar
  23. Rizzo WB, Leshner RT, Odone A et al (1989) Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 39:1415–1422CrossRefPubMedGoogle Scholar
  24. Sassa T, Kihara A (2014) Metabolism of very long-chain fatty acids: genes and pathophysiology. Biomol Ther 22:83–92CrossRefGoogle Scholar
  25. Sassa T, Wakashima T, Ohno Y, Kihara A (2014) Lorenzo’s oil inhibits ELOVL1 and lowers the level of sphingomyelin with a saturated very long-chain fatty acid. J Lipid Res 55:524–530CrossRefPubMedPubMedCentralGoogle Scholar
  26. Schackmann MJ, Ofman R, Dijkstra IM, Wanders RJ, Kemp S (2015) Enzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis. Biochim Biophys Acta 1851:231–237CrossRefPubMedGoogle Scholar
  27. Seedorf U, Brysch P, Engel T, Schrage K, Assmann G (1994) Sterol carrier protein X is peroxisomal 3-oxoacyl coenzyme a thiolase with intrinsic sterol carrier and lipid transfer activity. J Biol Chem 269:21277–21283PubMedGoogle Scholar
  28. Takemoto Y, Suzuki Y, Horibe R, Shimozawa N, Wanders RJ, Kondo N (2003) Gas chromatography/mass spectrometry analysis of very long chain fatty acids, docosahexaenoic acid, phytanic acid and plasmalogen for the screening of peroxisomal disorders. Brain Dev 25:481–487CrossRefPubMedGoogle Scholar
  29. Thomassen MS, Norseth J, Christiansen EN (1985) Long-term effects of high-fat diets on peroxisomal β-oxidation in male and female rats. Lipids 20:668–674CrossRefPubMedGoogle Scholar
  30. van Engen CE, Ofman R, Dijkstra IM et al (2016) CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids. Biochim Biophys Acta 1862:1861–1870CrossRefPubMedGoogle Scholar
  31. van Roermund CW, Visser WF, Ijlst L, Waterham HR, Wanders RJ (2011) Differential substrate specificities of human ABCD1 and ABCD2 in peroxisomal fatty acid β-oxidation. Biochim Biophys Acta 1811:148–152CrossRefPubMedGoogle Scholar
  32. Veerkamp JH, Zevenbergen JL (1986) Effect of dietary fat on total and peroxisomal fatty acid oxidation in rat tissues. Biochim Biophys Acta 878:102–109CrossRefPubMedGoogle Scholar
  33. Wanders RJA, Barth PG, Heymans HAS (2001) Single peroxisomal enzyme deficiencies. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The molecular and metabolic basis of inherited disease. McGraw-Hill, New York, pp 3219–3256Google Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Masashi Morita
    • 1
    Email author
  • Ayako Honda
    • 2
  • Akira Kobayashi
    • 1
  • Yuichi Watanabe
    • 1
  • Shiro Watanabe
    • 3
  • Kosuke Kawaguchi
    • 1
  • Shigeo Takashima
    • 2
  • Nobuyuki Shimozawa
    • 2
  • Tsuneo Imanaka
    • 1
    • 4
  1. 1.Department of Biological Chemistry, Graduate School of Medicine and Pharmaceutical SciencesUniversity of ToyamaToyamaJapan
  2. 2.Division of Genomic Research, Life Science Research CenterGifu UniversityGifuJapan
  3. 3.Division of Nutritional Biochemistry, Institute of Natural MedicineUniversity of ToyamaToyamaJapan
  4. 4.Faculty of Pharmaceutical SciencesHiroshima International UniversityKureJapan

Personalised recommendations